US FDA approves Watson's Gelnique for overactive bladder
This article was originally published in Scrip
Executive Summary
The US FDAhas approved Watson Pharmaceuticals' muscarinic antagonist Gelnique (oxybutynin chloride) gel 10% – a topical treatment for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.